Xylazine and Fentanyl: What It Changes in Detox

Someone arrives at a residential program in Los Angeles believing they have been using fentanyl. They have — but for much of the past year, what they bought also contained xylazine, a veterinary sedative that is not an opioid and does not respond to any of the medications used to treat opioid withdrawal. They usually do not know this. What they know is that the last few attempts to stop felt different from the ones before: sedation that went deeper than expected, a withdrawal that arrived sooner and refused to settle, and sores on the forearms that were not healing the way sores normally heal.

Xylazine has quietly changed what detoxing from street opioids actually involves. This article explains what the drug is, why it complicates withdrawal, what it means for overdose response, and what safe, medically supervised care looks like — particularly in a small residential setting.

What xylazine is, and how it ended up in the opioid supply

Xylazine is an alpha-2 adrenergic agonist approved in the United States only for veterinary sedation and pain control in animals such as horses and cattle. It has never been approved for use in people. Pharmacologically it sits closer to clonidine than to heroin or fentanyl: it produces heavy sedation, lowers blood pressure and heart rate, and slows the body down without touching opioid receptors at all.

In the illicit supply it appears as an adulterant, most often mixed into fentanyl, and it is commonly called “tranq” on the street. The National Institute on Drug Abuse describes it as an increasingly common contaminant and connects its spread to overdose deaths in a growing number of states. Surveillance first flagged heavy concentrations in the Northeast; the pattern has moved west, and providers in California now encounter it often enough that it belongs in every intake conversation rather than in a footnote.

The practical problem for anyone using street opioids is that there is no way to know what is in the product. Xylazine cannot be identified by look, smell, or effect in the moment, and it is not detected on standard hospital or treatment-center urine drug screens unless the test is specifically ordered.

Why xylazine makes opioid withdrawal harder to manage

The core difficulty is that someone can be physically dependent on two different classes of drug simultaneously while believing they are dependent on one. Buprenorphine and methadone are the evidence-based tools for opioid withdrawal, and they work well for the opioid half of the picture — the NIDA overview of fentanyl reflects how central these medications have become to opioid treatment. They do nothing at all for the xylazine half.

What tends to remain after the opioid symptoms are addressed is an alpha-2 agonist withdrawal: severe anxiety and agitation, insomnia that does not respond to the usual measures, elevated blood pressure and heart rate, sweating, and a restless, crawling discomfort that people struggle to describe. Clinicians report that this component is often more prolonged and harder to quiet than opioid withdrawal alone, though the research base is still young and specific protocols are not yet standardized. Anyone who tells you there is a settled, published protocol for xylazine withdrawal is getting ahead of the evidence.

This matters enormously for the first seventy-two hours. A person who expected to feel meaningfully better once buprenorphine was started, and who instead still feels terrible on day three, is at real risk of concluding that treatment does not work for them and leaving. Explaining in advance why the timeline may look different is not a small courtesy; it is a retention intervention. Supervised medical detox exists partly so that someone is monitoring vital signs and adjusting comfort medications through exactly that window.

It is also why intake asks about every substance, not just the primary one. Polysubstance use is the norm rather than the exception, and the combinations change the medical stakes. Alcohol and benzodiazepine withdrawal in particular can produce seizures and, in severe cases, become life-threatening — neither should ever be stopped abruptly without medical supervision. Someone using fentanyl who is also drinking daily or taking benzodiazepines needs that assessed before any taper begins.

Naloxone still matters — but it does not reverse xylazine

Naloxone reverses opioid effects. It has no action on xylazine, because xylazine is not an opioid. This has led to a dangerous piece of misinformation: that naloxone is pointless when tranq is involved.

It is not. Nearly all xylazine exposure in the United States occurs alongside fentanyl, and the opioid is what suppresses breathing. Naloxone should still be given in any suspected overdose. The difference is what to expect afterward — the person may remain heavily sedated even after the opioid is reversed, because the sedative component is still active. That sedation is not a sign the naloxone failed. Call 911, give rescue breaths if breathing is inadequate, stay with the person, and be prepared for a slower, less dramatic return to consciousness than the one people describe from opioid-only overdoses.

Skin wounds belong in the clinical picture

Xylazine has been associated with severe skin ulcers that can develop at sites unrelated to where someone injected, and that behave differently from ordinary abscesses — slower to heal, deeper, more prone to serious infection. These are genuine medical wounds, not a cosmetic problem, and people are often deeply ashamed of them, which delays care further.

A residential program is not a wound clinic. What a good program does is look, ask without judgment, and coordinate appropriate outside medical care rather than treating the wounds as someone else’s problem to sort out after discharge.

What supervised care looks like in a six-bed residence

Annandale Behavioral Health is a small private residence — six beds, not a campus. That scale is the relevant clinical fact here rather than a marketing line. When the withdrawal course is unpredictable and partly outside published protocol, the thing that keeps someone safe is staff who know each resident well enough to notice that today’s agitation is different from yesterday’s.

Care during this period generally involves regular monitoring of vital signs, medication for the opioid component where clinically appropriate, targeted comfort medication for sleep, nausea, and autonomic symptoms, and close attention to hydration and nutrition, which suffer badly in the weeks before someone comes in. Medication-assisted treatment is one component, not the whole of it, and decisions about starting, continuing, or tapering medication are individual and made with a clinician.

Once the acute phase passes, the work shifts into the ordinary substance of residential treatment — individual therapy, group work, sleep and routine, and building a plan that survives the first month at home.

Conditions treated alongside substance use

Most people who come in for opioid use disorder are carrying something else as well. Depression, anxiety, PTSD and unresolved trauma, bipolar disorder, ADHD, insomnia, chronic pain, and grief all commonly sit underneath sustained substance use, and treating the substance use while ignoring them tends not to hold. Dual diagnosis care means these are addressed concurrently, as part of treatment for the substance use disorder — which is what a licensed substance use disorder facility is set up to do.

Chronic pain deserves specific mention in this context. A meaningful number of people using street opioids started with pain that was real and is still real. That conversation has to happen honestly during treatment, or the pain simply waits at the other end.

Questions worth asking a program

If you are calling programs on someone’s behalf, or your own, a few questions separate the ones that are prepared from the ones that are not. Do you screen for xylazine exposure at intake, and how? What do you do differently when the withdrawal does not follow the expected opioid timeline? How do you handle wounds? Who is on site overnight during the first week? What happens if someone wants to leave on day three?

Talking to someone today

If you are trying to decide whether residential care is the right step, you can reach Annandale Behavioral Health at (855) 778-8668. The conversation is a clinical one — what has been used, for how long, what has been tried before — and it is meant to figure out what level of care is appropriate, including saying so if that is somewhere other than here.

For general information and free, confidential referrals available around the clock, SAMHSA’s National Helpline is 1-800-662-HELP (4357). If you or someone with you is in immediate danger, call 911. For a mental health crisis, the 988 Suicide and Crisis Lifeline is available by call or text. To speak with our admissions team directly, call (855) 778-8668.

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. It does not establish a clinician-patient relationship. Withdrawal from opioids, alcohol, and benzodiazepines can carry serious medical risk and should be managed with professional supervision. Please consult a qualified healthcare provider about your own circumstances. Outcomes vary, and no treatment program can guarantee a particular result.